Propanc Biopharma Inc
OTC:PPCB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BGIN Blockchain Ltd
NASDAQ:BGIN
|
SG |
|
A
|
ACS Actividades de Construccion y Servicios SA
VSE:ACS
|
ES |
|
J
|
Jinlihua Electric Co Ltd
SZSE:300069
|
CN |
|
Zhejiang Gongdong Medical Technology Co Ltd
SSE:605369
|
CN |
|
N
|
Newregen Inc
OTC:NREG
|
US |
|
H
|
Health Advance Inc
OTC:HADV
|
US |
|
C
|
Cosigo Resources Ltd
OTC:COSRF
|
CA |
|
Santeon Group Inc
OTC:SANT
|
US |
|
Isonics Corp
OTC:ISON
|
US |
|
C
|
Changchun Zhiyuan New Energy Equipment Co Ltd
SZSE:300985
|
CN |
Propanc Biopharma Inc
Research & Development
Propanc Biopharma Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Propanc Biopharma Inc
OTC:PPCB
|
Research & Development
-$248.1k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$60.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Research & Development
-AU$7.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$171.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$65m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
-36%
|
|
Propanc Biopharma Inc
Glance View
Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate PRP is a pharmaceutical composition consisting of two pancreatic proenzymes trypsinogen and chymotrypsinogen for treating cancer. PRP is an approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that targets and eradicates cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. PRP is a therapy based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas and could represent the body’s primary defense against cancer.
See Also
What is Propanc Biopharma Inc's Research & Development?
Research & Development
-248.1k
USD
Based on the financial report for Jun 30, 2024, Propanc Biopharma Inc's Research & Development amounts to -248.1k USD.
What is Propanc Biopharma Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-2%
Over the last year, the Research & Development growth was 0%. The average annual Research & Development growth rates for Propanc Biopharma Inc have been -2% over the past three years .
